(See Use of DDAVP (desmopressin acetate tablets) Tablets in geriatric patients requires careful fluid intake restrictions Oral doses up to 0.2 mg/kg/day have been administered to dogs and rats for 6 months without any significant drug-related toxicities reported. care should be taken in dose selection, and it may be useful to monitor renal
Desmopressin for dogs, also known by the brand names DDAVP and Stimate, is a drug primarily used to treat central diabetes insipidus and, sometimes, von Willebrand's disease. Select one or more newsletters to continue. Betamethasone Soluble Tablets are a steroid medicine, prescribed for many different conditions, including serious illnesses. function. In most patients, doses of 0.1 mg to 0.2 mg produced optimal antidiuretic effects lasting up to eight hours. Usually, the change occurred
Very rare cases of hyponatremia have been reported from world-wide postmarketing experience in patients treated with DDAVP (desmopressin acetate). this effect is due to the development of binding antibodies, but may be due In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. No lessening of effect was observed in the 46 patients who were treated with The change in structure of arginine vasopressin to desmopressin acetate resulted in less vasopressor activity and decreased action on visceral smooth muscle relative to enhanced antidiuretic activity. July 2007. However, no causal connection between these events and desmopressin acetate has been established. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. The time to reach maximum Because elderly patients are more likely to have decreased renal function, In younger pediatric patients the dose must be individually adjusted in order to prevent an excessive decrease in plasma osmolality leading to hyponatremia and possible convulsions; dosing … but not with Several publications where desmopressin acetate was used in the management of diabetes insipidus during pregnancy are available; these include a few anecdotal reports of congenital anomalies and low birth weight babies. In these patients, the 0.2 mg tablets and the 0.01 mg intranasal spray exhibited similar pharmacodynamic profiles as did the 0.4 mg tablets and the 0.02 mg intranasal spray formulation. A fifteen year Swedish epidemiologic study of the use of desmopressin acetate in pregnant women with diabetes insipidus found the rate of birth defects to be no greater than that in the general population; however, the statistical power of this study is low. A total of 329 patients were evaluated for efficacy. In another study of adult diabetes insipidus patients previously controlled on DDAVP intranasal spray, after one week of self-titration from spray to tablets, patients' diuresis was controlled with 0.1 mg Two double-blind, randomized, placebo-controlled studies were conducted in 340 patients with primary nocturnal enuresis. If you experience any of the above side effects, you should contact your doctor or go to the nearest casualty department immediately. of All four dose formulations (0.01 mg IN, 0.02 mg IN, 0.2 mg PO and 0.4 mg PO) have a similar, pronounced pharmacodynamic effect on urine volume and urine osmolality. This change may be due to decreased responsiveness, or to shortened duration of effect. The usual dosage range is 0.1 mg to 1.2 mg PO per day, given in 2 to 3 divided doses. In a six month, open-label extension study, patients completing the placebo-controlled studies were started on 0.2 mg/day DDAVP, and the dose was progressively … Visit cvs.com …
A statistical separation from baseline did not occur at any dose or time point. of toxic reactions to this drug may be greater in patients with impaired renal impairment (defined as a creatinine clearance below 50ml/min).
Twenty-five (25) patients (11%) achieved a complete or near complete response (≤2 wet nights/2 weeks) and did not require titration to the 0.6 mg/day dose.
(See Infrequently, high doses of the intranasal formulations of DDAVP and DDAVP Injection have produced transient headache, nausea, flushing and mild abdominal cramps. In these patients, the 0.2 mg tablets and the 0.01 mg intranasal spray exhibited similar pharmacodynamic profiles as did the 0.4 mg tablets and the 0.02 mg intranasal spray formulation.